Evidence map›Paper›PMID 38345692›Full record

ArticleBreast cancer research and treatment2024

The impact of germline BRCA pathogenic variants in locally advanced, triple negative breast cancer treated with platinum-based neoadjuvant chemotherapy.

Raz Mutai, Iryna Kuchuk, Alexandra Goldshtein, Rinat Yerushalmi, Ofer Rotem, Adi Maisel Lotan, Tali Bdolah-Abram, Alberto Gabizon, Hadar Goldvaser

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research and treatment, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Trial
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Raz MutaiDavidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel.
Iryna KuchukFaculty of Medicine Tel-Aviv University, Tel-Aviv, Israel.
Alexandra GoldshteinDepartment of Military Medicine and "Tzameret", Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Rinat YerushalmiDavidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel.
Ofer RotemDavidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel.
Adi Maisel LotanPlastic Surgery Department, Shaare Zedek Medical Center, Faculty of Medicine, Hebrew University, Jerusalem, Israel.
Tali Bdolah-AbramFaculty of Medicine, Hebrew University, Jerusalem, Israel.
Alberto GabizonThe Helmsley Cancer Center, Shaare Zedek Medical Center, Faculty of Medicine, Hebrew University, 9103102, Jerusalem, Israel.
Hadar GoldvaserThe Helmsley Cancer Center, Shaare Zedek Medical Center, Faculty of Medicine, Hebrew University, 9103102, Jerusalem, Israel. hadar7g@gmail.com.ORCID http://orcid.org/0000-0002-9557-4634

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWhether germline BRCA (gBRCA) pathogenic variants (PV) affect prognosis of women with triple negative breast cancer (TNBC) and whether it has implications for treatment decisions in the neoadjuvant setting is unclear.

methodsThis is a retrospective two-center cohort study comprising all women with early stage TNBC who have completed genetic testing and were treated with neoadjuvant dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and carboplatin. All eligible patients treated between 10.2014 and 3.2020 were included. Data on clinico-pathological, pathological response, overall survival (OS) and disease-free survival (DFS) were evaluated. Differences in clinico-pathological features and outcomes were analyzed according to gBRCA status.

resultsSixty-four women were included in the final analysis, of which 31 had gBRCA PV (gBRCA carriers) and 33 were gBRCA wild-type. Clinico-pathological characteristics were similar between both groups. The odds for pathological complete response (pCR) were significantly higher in gBRCA carriers (74.2%) compared to BRCA wild-type women (48.5%), p = 0.035. At a median follow-up of 30 months, gBRCA carriers had significantly favorable OS (HR = 8.64, 95% CI 1.08-69.21, p = 0.042). The difference in DFS did not reach statistical significance (HR = 7.4, 95% CI 0.91-60.27, p = 0.062). The favorable OS for gBRCA carriers remained significant in multivariate analysis (p = 0.029) and was noted regardless of pathological response (p = 0.018).

conclusionCompared to wild-type, gBRCA carriers with locally advanced TNBC treated with neoadjuvant chemotherapy containing carboplatin had a higher pCR rate and better outcomes. These results strengthen the contention that gBRCA status should be considered when tailoring treatment decisions in women with locally advanced TNBC.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBRCA1 ProteinBRCA2 ProteinGerm-Line MutationNeoadjuvant TherapyTriple Negative Breast NeoplasmsAdultAgedCarboplatinCyclophosphamideDoxorubicinFemaleHumansMiddle AgedNeoplasm StagingPaclitaxelBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanCarboplatinCyclophosphamideDoxorubicinPaclitaxelBRCA mutationBreast cancerNeoadjuvant chemotherapyTriple negative

Identifiers

PMID38345692
PMCPMC11101505

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.